Subscribe to RSS
Download PDF
DOI: 10.1055/s-0042-1750202
Oral Antiseptic Spray Containing Phthalocyanine Solution Reduced Saliva SARS-CoV-2 Viral Load: Case Series
Funding Dr. F. V. Vilhena reports grants from TRIALS Inc, during the conduct of the study; in addition, Dr. F. V. Vilhena has a patent.
Introduction
Since the 2019 global dissemination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), scientific advancements have enabled researchers to develop different types of vaccines and other forms of prevention and treatment against coronavirus disease 2019 (COVID-19).[1] The oral cavity is related to the development of COVID-19 as it allows the virus direct access into the body.[2] [3] [4] According to the literature, clinical evidence has demonstrated that antiviral oral solutions can inactivate SARS-CoV-2 and reduce clinical symptoms and severity of COVID-19.[2] [5] [6] [7] [8] Based on previous in vitro studies employing antiviral phthalocyanine derivative (APD) solutions,[6] [9] this case series evaluated the action of an APD oral spray for viral load reduction in COVID-19 hospitalized patients.
Publication History
Received: 22 August 2021
Accepted: 02 May 2022
Article published online:
14 July 2022
© 2022. Fundação Otorrinolaringologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Bakadia BM, He F, Souho T. et al. Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. Biomed Pharmacother 2021; 133: 111008
- 2 Huang N, Pérez P, Kato T. et al; NIH COVID-19 Autopsy Consortium, HCA Oral and Craniofacial Biological Network. SARS-CoV-2 infection of the oral cavity and saliva. Nat Med 2021; 27 (05) 892-903
- 3 Fernandes Matuck B, Dolhnikoff M, Maia GVA. et al. Periodontal tissues are targets for Sars-Cov-2: a post-mortem study. J Oral Microbiol 2020; 13 (01) 1848135
- 4 Matuck BF, Dolhnikoff M, Duarte-Neto AN. et al. Salivary glands are a target for SARS-CoV-2: a source for saliva contamination. J Pathol 2021; 254 (03) 239-243
- 5 Mateos-Moreno MV, Mira A, Ausina-Márquez V, Ferrer MD. Oral antiseptics against coronavirus: in-vitro and clinical evidence. J Hosp Infect 2021; 113: 30-43
- 6 Santos PSS, Fonseca OrcinaB, Machado RRG. et al. Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: Randomised trial. Sci Rep 2021 Oct 7. PMID: 34620904; PMCID: PMC8497631.11(01):19937. Doi: 10.1038/s41598-021-99013
- 7 da Fonseca Orcina B, Vilhena FV, Cardoso de Oliveira R. et al. A Phthalocyanine Derivate Mouthwash to Gargling/Rinsing as an Option to Reduce Clinical Symptoms of COVID-19: Case Series. Clin Cosmet Investig Dent 2021; 13: 47-50
- 8 Carrouel F, Valette M, Gadea E. et al. Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial. Clin Microbiol Infect 2021; 27 (10) 1494-1501
- 9 Santos C, da Fonseca Orcina B, Brito Reia VC. et al. Virucidal activity of the antiseptic mouthwash and dental gel containing anionic phthalocyanine derivative: in vitro study. Clin Cosmet Investig Dent 2021; 13: 269-274
- 10 Huang YH, Huang JT. Use of chlorhexidine to eradicate oropharyngeal SARS-CoV-2 in COVID-19 patients. J Med Virol 2021; 93 (07) 4370-4373